{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:18:23Z","timestamp":1783487903312,"version":"3.55.0"},"reference-count":35,"publisher":"The Endocrine Society","issue":"2","license":[{"start":{"date-parts":[[2019,1,9]],"date-time":"2019-01-09T00:00:00Z","timestamp":1546992000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,2,1]]},"DOI":"10.1210\/js.2018-00366","type":"journal-article","created":{"date-parts":[[2019,1,9]],"date-time":"2019-01-09T13:18:10Z","timestamp":1547039890000},"page":"496-503","source":"Crossref","is-referenced-by-count":57,"title":["Immune Checkpoint Blockade Anti\u2013PD-L1 as a Trigger for Autoimmune Polyendocrine Syndrome"],"prefix":"10.1210","volume":"3","author":[{"given":"Giulia","family":"Lanzolla","sequence":"first","affiliation":[{"name":"Endocrinology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Coppelli","sequence":"additional","affiliation":[{"name":"Diabetes Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirco","family":"Cosottini","sequence":"additional","affiliation":[{"name":"Neuroradiology, Department of Translational Research and New Technologies in Medicine and Surgery, University Hospital Pisa, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Del Prato","sequence":"additional","affiliation":[{"name":"Diabetes Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Marcocci","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1010-3110","authenticated-orcid":false,"given":"Isabella","family":"Lupi","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2019,1,8]]},"reference":[{"issue":"12","key":"key\n\t\t\t\t2019020609193558400_B1","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMra1713301","article-title":"Autoimmune polyendocrine syndromes","volume":"378","author":"Husebye","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"key\n\t\t\t\t2019020609193558400_B2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine toxicity of cancer immunotherapy targeting immune checkpoints","volume":"40","author":"Chang","year":"2019","journal-title":"Endocr Rev"},{"issue":"5","key":"key\n\t\t\t\t2019020609193558400_B3","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1210\/jc.2014-1049","article-title":"Detection of pituitary antibodies by immunofluorescence: approach and results in patients with pituitary diseases","volume":"99","author":"Ricciuti","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"230","key":"key\n\t\t\t\t2019020609193558400_B4","doi-asserted-by":"crossref","first-page":"230ra45","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci Transl Med"},{"key":"key\n\t\t\t\t2019020609193558400_B5","unstructured":"RRID: AB_2340569."},{"key":"key\n\t\t\t\t2019020609193558400_B6","unstructured":"RRID: AB_2756403."},{"key":"key\n\t\t\t\t2019020609193558400_B7","unstructured":"RRID: AB_2756402."},{"key":"key\n\t\t\t\t2019020609193558400_B8","unstructured":"RRID: AB_2314008."},{"key":"key\n\t\t\t\t2019020609193558400_B9","unstructured":"RRID: AB_2532462."},{"key":"key\n\t\t\t\t2019020609193558400_B10","unstructured":"RRID: AB_10989917."},{"key":"key\n\t\t\t\t2019020609193558400_B11","unstructured":"RRID: AB_2630356."},{"key":"key\n\t\t\t\t2019020609193558400_B12","unstructured":"RRID: AB_2338897."},{"issue":"6","key":"key\n\t\t\t\t2019020609193558400_B13","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1111\/jdi.12531","article-title":"Fulminant type 1 diabetes mellitus with anti-programmed cell death-1 therapy","volume":"7","author":"Okamoto","year":"2016","journal-title":"J Diabetes Investig"},{"issue":"5","key":"key\n\t\t\t\t2019020609193558400_B14","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S1471-4906(01)01888-9","article-title":"PD-1: an inhibitory immunoreceptor involved in peripheral tolerance","volume":"22","author":"Nishimura","year":"2001","journal-title":"Trends Immunol"},{"issue":"1","key":"key\n\t\t\t\t2019020609193558400_B15","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1084\/jem.20022125","article-title":"The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice","volume":"198","author":"Ansari","year":"2003","journal-title":"J Exp Med"},{"issue":"10","key":"key\n\t\t\t\t2019020609193558400_B16","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1111\/j.1464-5491.2006.01951.x","article-title":"Phenotypic and genetic analyses of T-cell-mediated immunoregulation in patients with type 1 diabetes","volume":"23","author":"Tsutsumi","year":"2006","journal-title":"Diabet Med"},{"issue":"3","key":"key\n\t\t\t\t2019020609193558400_B17","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/cei.12603","article-title":"Low programmed cell death-1 (PD-1) expression in peripheral CD4(+) T cells in Japanese patients with autoimmune type 1 diabetes","volume":"180","author":"Fujisawa","year":"2015","journal-title":"Clin Exp Immunol"},{"issue":"9","key":"key\n\t\t\t\t2019020609193558400_B18","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1210\/jc.2018-00728","article-title":"Programmed cell death-1 (PD-1) inhibitor induced type 1 diabetes mellitus: mini-review","volume":"103","author":"Clotman","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"key\n\t\t\t\t2019020609193558400_B19","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1016\/j.ajpath.2016.08.020","article-title":"Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: insights into pathogenesis from an autopsy series","volume":"186","author":"Caturegli","year":"2016","journal-title":"Am J Pathol"},{"issue":"12","key":"key\n\t\t\t\t2019020609193558400_B20","doi-asserted-by":"crossref","first-page":"5139","DOI":"10.1210\/jc.2009-1404","article-title":"Programmed death ligand 1 (PD-L1) gene variants contribute to autoimmune Addison\u2019s disease and Graves\u2019 disease susceptibility","volume":"94","author":"Mitchell","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"key\n\t\t\t\t2019020609193558400_B21","doi-asserted-by":"crossref","first-page":"e182","DOI":"10.1016\/j.jtho.2017.07.021","article-title":"Nivolumab-induced acute diabetes mellitus and hypophysitis in a patient with advanced pulmonary pleomorphic carcinoma with a prolonged tumor response","volume":"12","author":"Marchand","year":"2017","journal-title":"J Thorac Oncol"},{"issue":"2","key":"key\n\t\t\t\t2019020609193558400_B22","first-page":"303","article-title":"A case of multiple immune toxicities from ipilimumab and pembrolizumab treatment","volume":"15","author":"Humayun","year":"2016","journal-title":"Hormones (Athens)"},{"issue":"5","key":"key\n\t\t\t\t2019020609193558400_B23","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1097\/CMR.0000000000000384","article-title":"Fulminant type 1 diabetes after adjuvant ipilimumab therapy in cutaneous melanoma","volume":"27","author":"Tsiogka","year":"2017","journal-title":"Melanoma Res"},{"issue":"11","key":"key\n\t\t\t\t2019020609193558400_B24","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1007\/s00262-017-2033-8","article-title":"Autoimmune diabetes induced by PD-1 inhibitor-retrospective analysis and pathogenesis: A case report and literature review","volume":"66","author":"Gauci","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"key\n\t\t\t\t2019020609193558400_B25","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","article-title":"Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy","volume":"60","author":"Hofmann","year":"2016","journal-title":"Eur J Cancer"},{"issue":"1","key":"key\n\t\t\t\t2019020609193558400_B26","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1159\/000456540","article-title":"Autoimmune diabetes and thyroiditis complicating treatment with nivolumab","volume":"10","author":"Li","year":"2017","journal-title":"Case Rep Oncol"},{"key":"key\n\t\t\t\t2019020609193558400_B27","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s40425-016-0196-z","article-title":"Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy","volume":"4","author":"Lowe","year":"2016","journal-title":"J Immunother Cancer"},{"issue":"4","key":"key\n\t\t\t\t2019020609193558400_B28","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.2337\/dc14-2349","article-title":"Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy","volume":"38","author":"Hughes","year":"2015","journal-title":"Diabetes Care"},{"issue":"6","key":"key\n\t\t\t\t2019020609193558400_B29","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00262-016-1835-4","article-title":"A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: Presentation, management and outcome","volume":"65","author":"Hansen","year":"2016","journal-title":"Cancer Immunol Immunother"},{"issue":"11","key":"key\n\t\t\t\t2019020609193558400_B30","doi-asserted-by":"crossref","first-page":"e182","DOI":"10.2337\/dc15-1331","article-title":"Anti-PD1 pembrolizumab can induce exceptional fulminant type 1 diabetes","volume":"38","author":"Gaudy","year":"2015","journal-title":"Diabetes Care"},{"issue":"5","key":"key\n\t\t\t\t2019020609193558400_B31","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s00592-016-0872-y","article-title":"Anti-programmed cell death 1 therapy triggering diabetic ketoacidosis and fulminant type 1 diabetes","volume":"53","author":"Kong","year":"2016","journal-title":"Acta Diabetol"},{"issue":"1","key":"key\n\t\t\t\t2019020609193558400_B32","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.diabet.2016.05.007","article-title":"Autoimmune diabetes superimposed on type 2 diabetes in a patient initiated on immunotherapy for lung cancer","volume":"43","author":"Alhusseini","year":"2017","journal-title":"Diabetes Metab"},{"issue":"3","key":"key\n\t\t\t\t2019020609193558400_B33","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S2213-8587(13)70031-7","article-title":"Ipilimumab-induced autoimmune adrenalitis","volume":"1","author":"Min","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"key\n\t\t\t\t2019020609193558400_B34","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/CJI.0b013e318156e47e","article-title":"Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis","volume":"30","author":"Yang","year":"2007","journal-title":"J Immunother"},{"issue":"6","key":"key\n\t\t\t\t2019020609193558400_B35","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1210\/js.2017-00170","article-title":"Polyendocrinopathy resulting from pembrolizumab in a patient with a malignant melanoma","volume":"1","author":"Paepegaey","year":"2017","journal-title":"J Endocrine Soc"}],"container-title":["Journal of the Endocrine Society"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jes\/article-pdf\/3\/2\/496\/27716245\/js.2018-00366.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,10]],"date-time":"2022-09-10T00:12:04Z","timestamp":1662768724000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jes\/article\/3\/2\/496\/5273786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,8]]},"references-count":35,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,1,8]]},"published-print":{"date-parts":[[2019,2,1]]}},"URL":"https:\/\/doi.org\/10.1210\/js.2018-00366","relation":{},"ISSN":["2472-1972"],"issn-type":[{"value":"2472-1972","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,2]]},"published":{"date-parts":[[2019,1,8]]}}}